 LOS ANGELES, June 08, 2020 GLOBE NEWSWIRE -- ENOB - Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the completion of an Initial Targeted Engagement for Regulatory Advice INTERACT meeting with the U.S. Food and Drug Administration FDA Center for Biologics Evaluation and Research CBER Office of Tissues and Advanced Therapies OTAT. The meeting, which included management and scientists from Enochian BioSciences together with CBER OTAT staff, focused on the pathway forward for ENOB-HV-01. 